TRML
NASDAQTourmaline Bio Inc.
Tourmaline Bio Inc. (TRML) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. There were no new wire items for TRML in the last 30 days. The most recent was published Nov 17, 2025.
Latest news
25 items- SECSEC Form EFFECT filed by Tourmaline Bio Inc.EFFECT - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECSEC Form EFFECT filed by Tourmaline Bio Inc.EFFECT - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tourmaline Bio Inc.SCHEDULE 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
- SECSEC Form 15-12G filed by Tourmaline Bio Inc.15-12G - Tourmaline Bio, Inc. (0001827506) (Filer)
- INSIDERSEC Form 4 filed by Director Siegall Clay B4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- INSIDERDirector Mcdade Mark closing all direct ownership in the company (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- INSIDERDirector Kantoff Aaron closing all direct ownership in the company (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- INSIDERDirector Thiara Parvinder closing all direct ownership in the company (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- INSIDERDirector Castelein Caley closing all direct ownership in the company (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- INSIDERDirector Srivastava Sapna closing all direct ownership in the company (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- INSIDERChief Regulatory Officer Johnson Kevin Bruce returned 11,046 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- INSIDERCBO, GC and Secretary Middlekauff W Bradford returned 8,213 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- INSIDERCFO Robinson Ryan F. closing all direct ownership in the company (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- INSIDERCEO Kulkarni Sandeep Chidambar returned 30,387 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- INSIDERChief Technology Officer Jones Susan Dana returned 3,152 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- INSIDERNew insider Novartis Ag claimed ownership of 24,030,382 shares (SEC Form 3)3 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- SECSEC Form S-8 POS filed by Tourmaline Bio Inc.S-8 POS - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECSEC Form S-8 POS filed by Tourmaline Bio Inc.S-8 POS - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECSEC Form S-8 POS filed by Tourmaline Bio Inc.S-8 POS - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECSEC Form S-8 POS filed by Tourmaline Bio Inc.S-8 POS - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECSEC Form S-8 POS filed by Tourmaline Bio Inc.S-8 POS - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECSEC Form S-8 POS filed by Tourmaline Bio Inc.S-8 POS - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECSEC Form POS AM filed by Tourmaline Bio Inc.POS AM - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECSEC Form POS AM filed by Tourmaline Bio Inc.POS AM - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECTourmaline Bio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Leadership Update, Financial Statements and Exhibits8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
TRML FAQ
7 questionsWhat is the latest news on TRML?
Quantisnow has not tracked any new filings, ratings or press releases for TRML in the last 30 days. The most recent wire item was published on November 17, 2025.Where does TRML stock trade?
Tourmaline Bio Inc. (TRML) is listed on NASDAQ.What sector and industry is TRML in?
Tourmaline Bio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Tourmaline Bio Inc. go public?
Tourmaline Bio Inc. (TRML) completed its IPO in 2021.What are analysts saying about TRML?
Tourmaline Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Chardan Capital Markets: Buy with a $70.00 price target on 2025-04-23. Recent price targets range from $41.00 to $70.00.What companies are similar to TRML?
Notable peers in the same industry include AMGN (Amgen Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.), GILD (Gilead Sciences Inc.). Compare TRML side-by-side with any of them on Quantisnow.How can I track TRML on Quantisnow?
Quantisnow aggregates Tourmaline Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TRML to receive live email and push alerts on every new disclosure.